miR-21 inhibitor suppresses cell proliferation and colony formation through regulating the PTEN/AKT pathway and improves paclitaxel sensitivity in cervical cancer cells

Du,Guohui; Cao,Dongmei; Meng,Lingzheng

doi:10.3892/mmr.2017.6340

miR-21 inhibitor suppresses cell proliferation and colony formation through regulating the PTEN/AKT pathway and improves paclitaxel sensitivity in cervical cancer cells

Authors:
- Guohui Du
- Dongmei Cao
- Lingzheng Meng
View Affiliations

Affiliations: Department of Pharmacy, Tangshan Maternity and Child Health Care Hospital, Tangshan, Hebei 063000, P.R. China
Published online on: March 16, 2017 https://doi.org/10.3892/mmr.2017.6340
Pages: 2713-2719

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the role and the molecular mechanisms underlying the effects of microRNA-21 (miR-21) on the proliferation, apoptosis and colony formation of cervical cancer cells, and to examine the role of miR-21 in mediating the sensitivity of cervical cancer cells to paclitaxel (PTX). Reverse transcription‑quantitative polymerase chain reaction was employed to determine the level of miR‑21 in various cervical cancer and normal cervical cells. The results revealed that the expression levels of miR-21 in cervical cancer cells were markedly higher when compared with normal cervical cells. Subsequently, a miR‑21 inhibitor or negative control (NC) was transfected into cervical cancer cells. Cell viability, colony formation and apoptosis were then analyzed using an MTT assay, crystal violet and Annexin V-fluorescein isothiocyanate/propidium iodide staining, respectively. The protein expression level of B-cell lymphoma‑2 (Bcl‑2), Bcl‑2‑associated X (Bax), programmed cell death 4 (PDCD4), survivin, c‑myc, phosphatase and tensin homolog (PTEN) and phosphorylated (p)‑AKT were determined by western blot analysis. The sensitivity of cervical cancer cells to PTX (25, 50 and 100 µg/ml) was characterized using an MTT assay. The results demonstrated that the miR-21 inhibitor promoted apoptosis of cervical cancer cells and suppressed their proliferation and colony formation when compared with the NC. In addition, the expression levels of Bcl‑2, survivin, c‑myc and p‑AKT were significantly downregulated in cells transfected with the miR‑21 inhibitor, whilst the expression levels of Bax, PDCD4 and PTEN were significantly upregulated. Furthermore, the miR‑21 inhibitor significantly enhanced the inhibition efficacy of PTX at a range of concentrations in cervical cancer cells. It was concluded that inhibition of miR‑21 suppressed cell proliferation and colony formation through regulating the PTEN/AKT pathway, and improved PTX sensitivity in cervical cancer cells. The results of the present study may contribute to the development of miRNA‑based cervical cancer therapy in the future.

View Figures

View References

1	Missaoui N, Hmissa S, Trabelsi A, Frappart L, Mokni M and Korbi S: Cervix cancer in Tunisia: Clinical and pathological study. Asian Pac J Cancer Prev. 11:235–238. 2010.PubMed/NCBI
2	Feng Y, Cao T, Wang Y, Huang H, Xie Y and Liu J: Neoadjuvant chemotherapy followed by conization to spare fertility in cases of locally advanced cervical cancer: A case report and review of the literature. Mol Clin Oncol. 5:411–416. 2016.PubMed/NCBI
3	Qin AQ, Liang ZG, Ye JX, Li J, Wang JL, Chen CX and Song HL: Significant efficacy of additional concurrent chemotherapy with radiotherapy for postoperative cervical cancer with risk factors: A systematic review and meta-analysis. Asian Pac J Cancer Prev. 17:3945–3951. 2016.PubMed/NCBI
4	Gambari R, Brognara E, Spandidos DA and Fabbri E: Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: New trends in the development of miRNA therapeutic strategies in oncology (Review). Int J Oncol. 49:5–32. 2016.PubMed/NCBI
5	Zeng K, Zheng W, Mo X, Liu F, Li M, Liu Z, Zhang W and Hu X: Dysregulated microRNAs involved in the progression of cervical neoplasm. Arch Gynecol Obstet. 292:905–913. 2015. View Article : Google Scholar : PubMed/NCBI
6	Shen Y, Wang P, Li Y, Ye F, Wang F, Wan X, Cheng X, Lu W and Xie X: miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer. Br J Cancer. 109:92–99. 2013. View Article : Google Scholar : PubMed/NCBI
7	Pedroza-Torres A, López-Urrutia E, Garcia-Castillo V, Jacobo-Herrera N, Herrera LA, Peralta-Zaragoza O, López-Camarillo C, De Leon DC, Fernández-Retana J, Cerna-Cortés JF and Pérez-Plasencia C: MicroRNAs in cervical cancer: Evidences for a miRNA profile deregulated by HPV and its impact on radio-resistance. Molecules. 19:6263–6281. 2014. View Article : Google Scholar : PubMed/NCBI
8	Liu S, Cheng X, Zheng H and Xie R: Clinical efficacy and safety of paclitaxel plus cisplatin neoadjuvant treatment on locally advanced cervical cancer. Zhongguo Linchuang Yaolixue Zazhi. 31:432–434. 2015.(In Chinese).
9	Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006. View Article : Google Scholar : PubMed/NCBI
10	Deftereos G, Corrie SR, Feng Q, Morihara J, Stern J, Hawes SE and Kiviat NB: Expression of mir-21 and mir-143 in cervical specimens ranging from histologically normal through to invasive cervical cancer. PLoS One. 6:e284232011. View Article : Google Scholar : PubMed/NCBI
11	Lui WO, Pourmand N, Patterson BK and Fire A: Patterns of known and novel small RNAs in human cervical cancer. Cancer Res. 67:6031–6043. 2007. View Article : Google Scholar : PubMed/NCBI
12	Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C and Zheng ZM: Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One. 3:e25572008. View Article : Google Scholar : PubMed/NCBI
13	Wang XM, Xu J, Cheng ZQ, Peng QZ, Hu JT, Gao LK, Zhang SF and Jin HT: Study on effects of microRNA-21 antisense oligonucleotide in vivo and in vitro on bionomics of human cervical squamous carcinoma cell lines SiHa. Zhonghua Bing Li Xue Za Zhi. 41:254–259. 2012.(In Chinese). PubMed/NCBI
14	Zhu W and Xu B: MicroRNA-21 identified as predictor of cancer outcome: A meta-analysis. PLoS One. 9:e1033732014. View Article : Google Scholar : PubMed/NCBI
15	Wang Y, Zhu Y, Lv P and Li L: Targeting miR-21 with AS-miR-21 suppresses aggressive growth of human tongue squamous cell carcinoma in vivo. Int J Clin Exp Pathol. 8:4773–4781. 2015.PubMed/NCBI
16	Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B and Bao JK: Programmed cell death pathways in cancer: A review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 45:487–498. 2012. View Article : Google Scholar : PubMed/NCBI
17	Zeestraten EC, Benard A, Reimers MS, Schouten PC, Liefers GJ, van de Velde CJ and Kuppen PJ: The prognostic value of the apoptosis pathway in colorectal cancer: A review of the literature on biomarkers identified by immunohistochemistry. Biomark Cancer. 5:13–29. 2013. View Article : Google Scholar : PubMed/NCBI
18	Zhang Y, Yang H, Barnie PA, Yang P, Su Z, Chen J, Jiao Z, Lu L, Wang S and Xu H: The expression of Toll-like receptor 8 and its relationship with VEGF and Bcl-2 in cervical cancer. Int J Med Sci. 11:608–613. 2014. View Article : Google Scholar : PubMed/NCBI
19	Fernandes AT, Rocha NP, Vendrame E, Russomano F, Grinsztejn BJ, Friedman RK, Pinto AC, Klumb EM, Avvad E, Macedo J, et al: Polymorphism in apoptotic BAX (−248G>A) gene but not in anti-apoptotic BCL2 (−938C>A) gene and its protein and mRNA expression are associated with cervical intraepithelial neoplasia. Apoptosis. 20:1347–1357. 2015. View Article : Google Scholar : PubMed/NCBI
20	Huang Y, He Y and Li J: MicroRNA-21: A central regulator of fibrotic diseases via various targets. Curr Pharm Des. 21:2236–2242. 2015. View Article : Google Scholar : PubMed/NCBI
21	Yao Q, Xu H, Zhang QQ, Zhou H and Qu LH: MicroRNA-21 promotes cell proliferation and down-regulates the expression of programmed cell death 4 (PDCD4) in HeLa cervical carcinoma cells. Biochem Biophys Res Commun. 388:539–542. 2009. View Article : Google Scholar : PubMed/NCBI
22	Lankat-Buttgereit B and Göke R: The tumour suppressor Pdcd4: Recent advances in the elucidation of function and regulation. Biol Cell. 101:309–317. 2009. View Article : Google Scholar : PubMed/NCBI
23	Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S and Allgayer H: MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 27:2128–2136. 2008. View Article : Google Scholar : PubMed/NCBI
24	Chen Y, Liu W, Chao T, Zhang Y, Yan X, Gong Y, Qiang B, Yuan J, Sun M and Peng X: MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G. Cancer Lett. 272:197–205. 2008. View Article : Google Scholar : PubMed/NCBI
25	Roy K, Singh N, Kanwar RK and Kanwar JR: Survivin modulators: An updated patent review (2011–2015). Recent Pat Anticancer Drug Discov. 11:152–169. 2016. View Article : Google Scholar : PubMed/NCBI
26	Lu D, Yin X and Xiao Q: Expressions of PTEN and Survivin in the progression of cervical neoplasia and their clinical significances. Zhongguo Fuyou Baojian. 28:4721–4724. 2013.(In Chinese).
27	Hu Q and Liu K: The expression of CIP2A and c-Myc and their correlation analysis in cervical carcinoma tissues. Zhong Qing Yi Xue Bian Ji Bu. 44:1072–1074. 2015.(In Chinese).
28	Wang Y and Dai B: PTEN genomic deletion defines favorable prognostic biomarkers in localized prostate cancer: A systematic review and meta-analysis. Int J Clin Exp Med. 8:5430–5437. 2015.PubMed/NCBI
29	Wang LL, Hao S, Zhang S, Guo LJ, Hu CY, Zhang G, Gao B, Zhao JJ, Jiang Y, Tian WG, et al: PTEN/PI3K/AKT protein expression is related to clinicopathologic features and prognosis in breast cancer with axillary lymph node metastases. Hum Pathol pii. S0046–8177. 2016.
30	Bu L, Ma Y and Shi S: Expressions of CD31, CD105 and PTEN in cervical cancer and the clinical pathological significance. Zhongguo Fuyou Baojian. 30:1446–1449. 2015.
31	Rizvi MM, Alam MS, Mehdi SJ, Ali A and Batra S: Allelic loss of 10q23.3, the PTEN gene locus in cervical carcinoma from Northern Indian population. Pathol Oncol Res. 18:309–313. 2012. View Article : Google Scholar : PubMed/NCBI
32	Qi Q, Ling Y, Zhu M, Zhou L, Wan M, Bao Y and Liu Y: Promoter region methylation and loss of protein expression of PTEN and significance in cervical cancer. Biomed Rep. 2:653–658. 2014.PubMed/NCBI
33	Lu D, Qian J, Yin X, Xiao Q, Wang C and Zeng Y: Expression of PTEN and survivin in cervical cancer: Promising biological markers for early diagnosis and prognostic evaluation. Br J Biomed Sci. 69:143–146. 2012.PubMed/NCBI
34	Schwarz JK, Payton JE, Rashmi R, Xiang T, Jia Y, Huettner P, Rogers BE, Yang Q, Watson M, Rader JS and Grigsby PW: Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer. Clin Cancer Res. 18:1464–1471. 2012. View Article : Google Scholar : PubMed/NCBI
35	Tao YJ, Li YJ, Zheng W, Zhao JJ, Guo MM, Zhou Y, Qin NL, Zheng J and Xu L: Antisense oligonucleotides against microRNA-21 reduced the proliferation and migration of human colon carcinoma cells. Cancer Cell Int. 15:772015. View Article : Google Scholar : PubMed/NCBI
36	Xu J, Zhang W, Lv Q and Zhu D: Overexpression of miR-21 promotes the proliferation and migration of cervical cancer cells via the inhibition of PTEN. Oncol Rep. 33:3108–3116. 2015.PubMed/NCBI
37	Eskander RN and Tewari KS: Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer. Curr Opin Obstet Gynecol. 26:314–321. 2014. View Article : Google Scholar : PubMed/NCBI